Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6090943 | Clinical Gastroenterology and Hepatology | 2015 | 8 Pages |
Abstract
Clinical response and mucosal healing were confirmed as independent predictors of long-term outcome from infliximab therapy in patients with UC. We identified additional factors (levels of pANCA, CRP, and albumin) to create a risk panel that predicts long-term outcomes of therapy. Serum levels of infliximab at week 14 of treatment also were associated with patient outcomes. Our risk panel and short-term serum levels of infliximab therefore might be used to guide therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, Anthony de Buck van Overstraeten, Thomas Billiet, Filip Baert, Albert Wolthuis, Gert Van Assche, Maja Noman, Ilse Hoffman, Andre D'Hoore, Ann Gils, Paul Rutgeerts, Marc Ferrante,